| Stanford University, MBA | 1990 |
Ross Jaffe specializes in early-stage investing in medical devices. He brings significant clinical insight and venture capital experience to Versant’s investing efforts. Ross co-founded Versant Ventures in 1999 after spending nine years at Brentwood Venture Capital where, as a general partner, he led investments in medical devices, drug delivery, and healthcare information systems companies.
Ross is a board-certified internist, having completed his residency training in Internal Medicine/Primary Care at the University of California, San Francisco, where he remained a part-time attending physician until 1995. Before and during medical school, he was an Analyst for Lewin and Associates, a healthcare consulting firm, and a Research Associate at Dartmouth Medical School.
Ross has served as a director of Ablation Frontiers, Aradigm, Atrionix, Micro Interventional Systems, Novacept, Pro•Duct Health, St. Francis Medical Technologies, Therasense, and Webster Laboratories. He currently serves on the boards of Acclarent, Alter-G, Calypso Medical Technologies, ICS, Insulet (NASDAQ: PODD), Portaero and Vital Therapies. He is also a director of the Western Association of Venture Capitalists (WAVC) and a member of the National Venture Capital Association (NVCA) Medical Industry Group.
